News

Neovacs and Stellar Biotechnologies Partner Up to Form Neostell SAS

Neovacs and Stellar Biotechnologies have collaborated to form a new biotech company called Neostell SAS. Neovacs will own 70 percent of the new company and Stellar Biotechnologies will own the remaining 30 percent. Neovacs is a European leader in immunotherapies developed to treat autoimmune diseases. It’s lead active immunotherapy candidate is IFNα-Kinoid,…

Antibody’s Role in Autoimmune Disease Is Focus of New Study

Dr. Jill Kramer at the University of Buffalo School of Dental Medicine will lead a research study into the role of a certain type of antibody in Sjögren’s syndrome and other autoimmune diseases, including lupus. The study, focused on determining whether IgM is indeed harmless or pathogenic, is funded by a National…

Lupus Research Institute Announces 2016 Research Grants

The Lupus Research Institute (LRI) recently announced this years’ research grants awarded to systemic lupus erythematosus (SLE) researchers. The topics vary, but all strive to either present a better understanding of why people develop lupus or to improve treatment for the disease. Two projects will investigate the link between bacteria…

Key Molecule in Lupus-linked Gene Identified, Opening New Therapy Possibilities

Yale researchers have discovered a new transcription factor governing the production of a gene related to conditions such as systemic lupus erythematosus (SLE). The discovery opens up the possibility of more personalized SLE treatment. The study, titled “Transcription factor ICBP90 regulates the MIF promoter and immune susceptibility locus“ and published in the …

Lupus Inflammation Linked to Fungal Infection May Have Control Mechanism

A recent study has identified two novel substances — an antioxidant and an anti-inflammatory agent — that can control the excessive inflammatory response to fungal infection often seen in patients with systemic lupus erythematosus (SLE). Earlier studies have shown that invasive fungal infection (IFI) with the fungus Candida albicans can be life-threatening for SLE patients.

Protocol for Lupus Advanced Stage Clinical Trial Submitted by XTL

XTL Biopharmaceuticals has announced it has submitted the full protocol for its advanced stage clinical trial of hCDR1 in the treatment of systemic lupus erythematosus (SLE, commonly referred to as lupus) to Yeda Research and Development Company in Israel. According to the Phase II clinical study titled “Safety…